Oslo, Norway, November 9, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced it will release its third
quarter 2023 financial results before the opening of financial markets on
Wednesday, November 15, 2023.

The Company will host a subsequent webcast presentation to review the financial
and operating results. A question-and-answer session will follow.

Third Quarter 2023 Webcast:

Date:		Wednesday, November 15, 2023
Time:		4 p.m. CET / 10 a.m. ET
Webcast:	https://event.webcasts.com/starthere.jsp?ei=1640257&tp_key=2a6664ef92


The financial report, as well as a live and archived webcast of the
presentation, can be accessed in the Financial Reports and Presentations section
of the Company's website: 
https://nykode.com/investors/financial-reports-and-presentations.  


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells (APC), which have been
shown to induce broad, strong, and long-lasting antigen specific immune
responses which correlates with clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer